We have achieved clinical proof of mechanism for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, in the Phase 1 FOCUS-01 trial. Clean safety profile through 3 dose levels, and clinical PK closely matches preclinical modeling.
https://t.co/IbI1P3XUPy
#NextGenLoading#AVCT
@Snaljapen Kan varmt reka AirPods PRO med dessa, sitter som en smäck även på riktigt långa pass.
https://t.co/IutRBkT5Fgöronkrokar+airpods&qid=1692184749&sprefix=öronkrokar+%2Caps%2C103&sr=8-7